Diligence memo · auto-generated · as of July 2, 2026
X-Co Holdings, LP
X-Co Holdings, LP looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
X-Co Holdings, LP operates in Biotechnology, based in Wilmington.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
X-Co Holdings, LP has raised $71M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $71M on 2015-12-29.
Most recent recorded round closed around 2015-12-29.
Valuation (modeled)modeled
Provath models X-Co Holdings, LP at approximately $2.9B (range $220M–$7.7B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.29× the median modeled value of Series C Biotechnology companies in 2013–2015 (41 peers) — value vs value, same stage and era. Within the normal band (129% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 10.5 yr ago; this sector typically re-raises about every 14 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 87% of Biotechnology peers (4293 compared).
Modeled value ranks above 97% of those peers.
Closest niche peers: Antigenics LLC/DE, Naurex Inc., Fluidigm Corp, Tengion Inc, Spark Therapeutics, Inc..
Peoplefiled
4 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.